WAUKESHA, Wis.--(BUSINESS WIRE)--GE Healthcare, a unit of General Electric Company (NYSE: GE), today announced that it has received U.S. Food and Drug Administration (FDA) approval for its new mobile mammography product that will improve access to breast cancer screening for millions of women around the world. The mobile Senographe® Essential is built on the company’s Senographe Essential platform, the next-generation of GE’s proven Senographe Full Field Digital Mammography systems.
